By Mill Chart
Last update: Nov 20, 2023
Consider GILEAD SCIENCES INC (NASDAQ:GILD) as a top pick for dividend investors, identified by our stock screening tool. NASDAQ:GILD shines in terms of profitability, solvency, and liquidity, all while paying a decent dividend. Let's dive deeper into the analysis.
ChartMill assigns a proprietary Dividend Rating to each stock. The score is computed by evaluating various valuation aspects, like the yield, the history, the dividend growth and sustainability. NASDAQ:GILD was assigned a score of 7 for dividend:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:GILD has achieved a 5 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:GILD, the assigned 8 is noteworthy for profitability:
Our Best Dividend screener lists more Best Dividend stocks and is updated daily.
Check the latest full fundamental report of GILD for a complete fundamental analysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
GILEAD SCIENCES INC
NASDAQ:GILD (4/26/2024, 7:00:00 PM)
After market: 65.5 +0.08 (+0.12%)65.42
+0.15 (+0.23%)
Explore these three dividend stocks trading near their 52-week lows, presenting compelling opportunities for income-oriented investors.
GILD earnings call for the period ending March 31, 2024.
GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gilead Sciences (NASDAQ:GILD) just reported results for the first quarter of 20...
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top S&P500 gainers and losers in today's after hours session.
Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury.
Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD).